{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT02357992","nct_id":"NCT02357992","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02357992. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.\n\n50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor.","label":"Stereotactic Radiotherapy (SRT)","type":"EXPERIMENTAL"}],"collaborators":["Varian Medical Systems"],"completion_date":{"date":"2021-09-17","type":"ACTUAL"},"conditions":["Lung Cancer"],"enrollment":{"count":122,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Stereotactic Body Radiotherapy (SABR)","otherNames":["SABR","XRT","Radiation therapy"],"type":"RADIATION"}],"last_update":"2022-10-14","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy","overall_status":"COMPLETED","phases":["NA"],"primary_completion_date":{"date":"2021-09-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Overall Survival (OS) at 3 Years","timeFrame":"3 years"}],"references":[{"citation":"Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA; STARS Lung Cancer Trials Group. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 Oct;22(10):1448-1457. doi: 10.1016/S1470-2045(21)00401-0. Epub 2021 Sep 13.","pmid":"34529930","type":"DERIVED"}],"start_date":{"date":"2010-04-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy","url":"https://clinicaltrials.gov/study/NCT02357992"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02357992"}